Alnylam Pharmaceuticals Inc R&D Day Transcript
Welcome to Alnylam's R&D Day 2023. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications. We're pleased that you've tuned in to hear about our progress across our portfolio.
Turning to our agenda. You could see that we have a very exciting lineup of presentations scheduled during our time together with some strategic perspective on how we are building our business and executing towards our R&D strategy to deliver our goals. We will then turn to deep dives on different elements of our pipeline spanning from our early and mid-stage pipeline to progress with zilebesiran as a potential treatment for hypertension, before closing with some R&D and commercial perspectives on our leading TTR franchise.
A few quick reminders before we dive in. This event is scheduled to run until 12:45, and we've incorporated a break into the agenda. We'll be hosting 2 live moderated Q&A sessions during the meeting. To ask a question, please type
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
